Smart Phone Game Designed to Help Find Cancer Treatments
|
By LabMedica International staff writers Posted on 12 Mar 2013 |
The goal of a recent event held in London (UK) during March 1-3, 2013, was to identify new and scientifically effective ways for the public sector to help analyze gene data, and enjoy doing it in the process.
Cancer Research UK (London) recently brought together the charity’s world-leading scientists in conjunction with technology titans—such as Facebook, Google, and Amazon Web Services—to design and develop a mobile game to accelerate the finding of cancer cures. This innovative approach means that anyone with a smart phone and five minutes on a bus or train will be able to play an enjoyable game that will simultaneously investigate vital scientific data. The first phase was for 40 computer programmers, graphic designers, gamers, and other specialists to take part in a weekend “GameJam,” or hackathon, to convert Cancer Research UK’s raw gene data into a game format, with a working title of GeneRun, for citizen scientists to play.
An agency will construct the game format developed through the GameJam, to be launched in summer 2013. The charity is investing comprehensively in ways to discover the genetic flaws fueling cancer to find new ways to diagnose and treat patients in a more targeted way based on their genetic fingerprint.
However, this research generates immense amounts of data that need to be analyzed. Developments in technology mean scientists can process data faster than ever to identify new patterns and faults in tumors. But much of it still needs to be analyzed by individuals instead of machines. The human eye can detect slight alterations that machines are not programmed to search for—leading to unanticipated findings, providing insights into the causes and processes of the disease.
This research is currently performed by trained scientists and can take years. However, with the collective a large number of individuals worldwide helping these scientists to analyze this information could drastically speed up research—and consequently, saving lives faster. Citizen science is a new way of including the public in scientific research outside the laboratory.
Prof. Carlos Caldas, senior group leader at the Cancer Research UK Cambridge Institute, University of Cambridge (UK), stated, “Future cancer patients will receive treatment targeted to the genetic fingerprint of their tumor and we hope this exciting project will bring forward the day this becomes a reality. We’re making great progress in understanding the genetic reasons cancer develops. But the clues to why some drugs will work and some won’t, are held in data which need to be analyzed by the human eye--and this could take years. By harnessing the collective power of citizen scientists we’ll accelerate the discovery of new ways to diagnose and treat cancer much more precisely.”
This was the charity’s second collaboration with the Citizen Science Alliance (UK) and was attended by games technology academics from City University London (UK) as well as a range of technology experts. The first game, Cell Slider, launched as a Beta test in October 2012 to study archived cancer tissue samples.
Teresa Carlson, vice president of worldwide public sector, Amazon Web Services, said, “It is exciting to be part of this project and use cloud technology, and ‘gamification’ of data, to help in driving research towards finding a cure for cancer. We have a long running relationship with Cancer Research UK, and many other institutes, in using the cloud to help accelerate research. We look forward to seeing the final GeneRun games and supporting this project towards its ultimate goal.”
Dr. Harpal Kumar, Cancer Research UK’s chief executive, remarked, “Through our GameJam event we’re bringing together the cream of the UK’s technology specialists with our scientists as a collaborative force to accelerate cures for cancer outside the laboratory. “By harnessing the collective force of the public, Cell Slider has already shown how we can dramatically reduce the analysis time for some of our clinical trials data from 18 to three months.”
Related Links:
Cancer Research UK
Citizen Science Alliance
Cancer Research UK (London) recently brought together the charity’s world-leading scientists in conjunction with technology titans—such as Facebook, Google, and Amazon Web Services—to design and develop a mobile game to accelerate the finding of cancer cures. This innovative approach means that anyone with a smart phone and five minutes on a bus or train will be able to play an enjoyable game that will simultaneously investigate vital scientific data. The first phase was for 40 computer programmers, graphic designers, gamers, and other specialists to take part in a weekend “GameJam,” or hackathon, to convert Cancer Research UK’s raw gene data into a game format, with a working title of GeneRun, for citizen scientists to play.
An agency will construct the game format developed through the GameJam, to be launched in summer 2013. The charity is investing comprehensively in ways to discover the genetic flaws fueling cancer to find new ways to diagnose and treat patients in a more targeted way based on their genetic fingerprint.
However, this research generates immense amounts of data that need to be analyzed. Developments in technology mean scientists can process data faster than ever to identify new patterns and faults in tumors. But much of it still needs to be analyzed by individuals instead of machines. The human eye can detect slight alterations that machines are not programmed to search for—leading to unanticipated findings, providing insights into the causes and processes of the disease.
This research is currently performed by trained scientists and can take years. However, with the collective a large number of individuals worldwide helping these scientists to analyze this information could drastically speed up research—and consequently, saving lives faster. Citizen science is a new way of including the public in scientific research outside the laboratory.
Prof. Carlos Caldas, senior group leader at the Cancer Research UK Cambridge Institute, University of Cambridge (UK), stated, “Future cancer patients will receive treatment targeted to the genetic fingerprint of their tumor and we hope this exciting project will bring forward the day this becomes a reality. We’re making great progress in understanding the genetic reasons cancer develops. But the clues to why some drugs will work and some won’t, are held in data which need to be analyzed by the human eye--and this could take years. By harnessing the collective power of citizen scientists we’ll accelerate the discovery of new ways to diagnose and treat cancer much more precisely.”
This was the charity’s second collaboration with the Citizen Science Alliance (UK) and was attended by games technology academics from City University London (UK) as well as a range of technology experts. The first game, Cell Slider, launched as a Beta test in October 2012 to study archived cancer tissue samples.
Teresa Carlson, vice president of worldwide public sector, Amazon Web Services, said, “It is exciting to be part of this project and use cloud technology, and ‘gamification’ of data, to help in driving research towards finding a cure for cancer. We have a long running relationship with Cancer Research UK, and many other institutes, in using the cloud to help accelerate research. We look forward to seeing the final GeneRun games and supporting this project towards its ultimate goal.”
Dr. Harpal Kumar, Cancer Research UK’s chief executive, remarked, “Through our GameJam event we’re bringing together the cream of the UK’s technology specialists with our scientists as a collaborative force to accelerate cures for cancer outside the laboratory. “By harnessing the collective force of the public, Cell Slider has already shown how we can dramatically reduce the analysis time for some of our clinical trials data from 18 to three months.”
Related Links:
Cancer Research UK
Citizen Science Alliance
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







